Background
==========

Prostate cancer is a common type of cancer in men, with an estimated annual incidence of 238,590 cases \[[@b1-medscimonit-21-1707]\]. Although most of the prostate cancer cases happen in the developed countries, recent years have witnessed the rapid increase in prostate cancer incidence in developing populations, including China \[[@b2-medscimonit-21-1707]\]. Prostate cancer is also one of the leading causes of cancer-related mortality, accounting for 10% of all male cancer-related deaths, in both Western and Asian populations \[[@b3-medscimonit-21-1707]\]. Considering the significance of the disease, there is a pressing need for identifying risk factors of prostate cancer, so that the disease can be detected at an early stage, which facilitates prostate cancer treatment and management.

The mechanism of prostate carcinogenesis is extremely complicated. However, it has been generally accepted that the etiology of prostate cancer is influenced by several factors such as smoking habits, age, ethnicity, and, importantly, genetic factors \[[@b4-medscimonit-21-1707]--[@b6-medscimonit-21-1707]\]. It has been shown previously that the latter could contribute to up to 42% of prostate cancer risk \[[@b6-medscimonit-21-1707]\]. Candidate gene association study (CGAS) is an established method for identifying genetic variants associated with a disease \[[@b7-medscimonit-21-1707]\]. The approach focuses only on genes that could be of relevance to the mechanism of the disease of interest \[[@b7-medscimonit-21-1707],[@b8-medscimonit-21-1707]\]. The specific polymorphisms that could either affect gene expression or the protein product of the chosen candidate genes were then selected. Subsequently, the frequencies of the polymorphic genotypes were compared between subjects with and without the disease, and statistical models were used to determine risk association \[[@b7-medscimonit-21-1707],[@b8-medscimonit-21-1707]\].

Many studies on prostate carcinogenesis have focused on the role of genetic factors that mediate inflammatory response \[[@b9-medscimonit-21-1707]--[@b12-medscimonit-21-1707]\], as inflammation has been extensively linked to the etiology of prostate cancer, although other mechanisms such as cell adhesion also plays an important role \[[@b13-medscimonit-21-1707],[@b14-medscimonit-21-1707]\]. Given the important role of inflammation in carcinogenesis, the present candidate gene association study focused on genes relevant to inflammation. Among all the proteins involved in inflammatory response, the nuclear factor-kappa B (NF-κB) pathway proteins, notably p50 (NF-κB1) and its critical inhibitor, IκBα, appeared to have the most important function. NF-κB activation can lead to the synthesis of several enzymes, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2, which catalyze the release of reactive oxygen species that damages adjacent cells. The NF-κB pathway has also been shown to regulate the production of many pro-inflammatory cytokines, such as TGF-β, TNF-α, IL-6, and IL-8, which further supports the role of NF-κB in inflammation. Inflammation causes various genomic lesions to the cells, which facilitates cancer development. Additionally, improper activation of NF-κB1 can cause enhanced cell proliferation and evasion of apoptosis, which are 2 of the cancer hallmarks. Therefore, under normal conditions, NF-κB1 is bound to IκBα inhibitor when its expression is not needed.

NF-κB1 and IκBα are encoded by *NFKB1* and *NFKBIA* genes, respectively. The impact of polymorphisms within the *NFKB1* and *NFKBIA* genes on cancer risk has been extensively investigated in a number of cancers \[[@b15-medscimonit-21-1707]--[@b21-medscimonit-21-1707]\], but surprisingly few studies have been performed on prostate cancer \[[@b22-medscimonit-21-1707],[@b23-medscimonit-21-1707]\]. The risk modulation effects of the polymorphisms were inconsistent in different studies, which could be because of the small sample sizes recruited and the ethnic background differences of subjects in different studies. The present study aimed to examine the association of *NFKB1*9-4 ATTG ins→del, *NFKBIA* 3′ untranslated region (UTR) A→G, -826CT and -881AG polymorphisms with risk of developing prostate cancer among Chinese in a large sample size.

Material and Methods
====================

Subjects
--------

Between September 2008 and June 2014, 936 newly diagnosed, histopathologically confirmed sporadic prostate cancer patients were randomly recruited from the First Affiliated Hospital of Bengbu Medical College, Bengbu Third People's Hospital, the Second Affiliated Hospital of Bengbu Medical College, the People's Liberation Army 123^rd^ Hospital China and Bengbu First People's Hospital. Based on medical records, patients who had family history of prostate cancer and those who suffered from malignancies other than prostate cancer were excluded. Healthy males (N=936) were randomly recruited from the general population as controls. Controls were matched with patients by age (±5 years). The age of the patients recruited ranged from 50 to 76 years old, with a mean of 62.0±6.89 years. The controls' ages ranged from 48 to 73 years old, with a mean of 61.4±7.11. Based on our previous preliminary findings (data not shown), the peak age of prostate cancer incidence in our population occurred at 60 years old. Therefore, subjects below 60 years old were categorized as "young", while those 60 years or above were categorized as "old" in our analysis. 442 of the patients and 389 of the controls were smokers, while the rest were nonsmokers. Information on the subjects' age was collected based on the medical registration form (which was in turn based on the official identity card of the People's Republic of China). On the other hand, information on the smoking habits was obtained from an interview with subjects on recruitment. All subjects were self-described ethnic Han Chinese. They were asked to sign a written informed consent before donating 3 ml blood for genetic analysis. The study was approved by the Medical Ethics Board (MEB) of Bengbu Medical College (approval no. BMC/1/IMO/2008.0415504).

Genotyping of polymorphisms
---------------------------

DNA was extracted from blood samples by using the TIANGEN DNA Purification Kit. All polymorphisms were genotyped by previously described PCR-RFLP technique (NFKB1, \[[@b15-medscimonit-21-1707]\]; NFKBIA 3′ UTR \[[@b21-medscimonit-21-1707]\], NFKBIA -826CT, and -881AG \[[@b19-medscimonit-21-1707]\]), with the researchers blinded to the case/control status of the samples. For *NFKB1* polymorphism, the PCR primers were TGGGCACAAGTCGTTTATGA (forward) and CTGGAGCCGGTAGGGAAG (reverse), while the restriction enzyme used was PflMI (Van91I). For *NFKBIA* 3′ UTR polymorphism, the PCR primers were GGCTGAAAGAACATGGACTTG (forward) and GTACACCATTTACAGGAGGG (reverse), while HaeIII was used for the digesting the PCR products. *NFKBIA* -826CT and -881AG polymorphisms were amplified simultaneously by using GGTCCTTAAGGTCCAATCG (forward) and GTTGTGGATACCTTGCACTA (reverse). *NFKBIA* -826CT polymorphism was digested by using BfaI, and *NFKBIA* -881AG polymorphism was digested by using TspRI. Approximately 10% of randomly selected samples were sequenced to confirm the genotypes.

Statistical analysis
--------------------

All analyses were performed by using SPSS version 17.0. Continuous variables were assessed by using the independent samples t-test and are presented as mean ±SD. Categorical variables were tested by using the chi-square test. The Hardy-Weinberg equilibrium was analyzed by using a goodness-of-fit chi-square test. An unconditional logistic regression model was performed to calculate the odds ratios (ORs) and their corresponding 95% confidence intervals (95% CI) to assess the association of the polymorphisms with prostate cancer risk. The overall ORs were also adjusted to age and smoking status of the subjects. A p-value \<0.05 was statistically significant.

Results
=======

Frequency of *NFKB1* and *NFKBIA* genotypes
-------------------------------------------

The frequency of *NFKB1* and *NFKBIA* genotypes in the 936 patients and 936 controls are shown in [Table 1](#t1-medscimonit-21-1707){ref-type="table"}. Significant differences in genotype frequency were observed between patients and controls for the *NFKB1*9-4 ATTG polymorphism (P=0.03), *NFKBIA* -826CT polymorphism (P\<0.01), and *NFKBIA* -881AG polymorphism (P\<0.01). The frequency for *NFKBIA* -826CT and -881AG polymorphisms was identical, indicating the presence of linkage disequilibrium (LD). In addition, the genotype frequency for all the polymorphisms followed Hardy-Weinberg Equilibrium ([Table 1](#t1-medscimonit-21-1707){ref-type="table"}).

Association of the SNPs and prostate cancer risk
------------------------------------------------

[Table 2](#t2-medscimonit-21-1707){ref-type="table"} showed the association of the SNPs and prostate cancer risk. Significant association was found for *NFKB1*9-4 ATTG, *NFKBIA* -826CT and -881AG polymorphisms, but not the *NFKBIA* 3′ UTR polymorphism. For *NFKB1*9-4 ATTG polymorphism, the ins/del genotype and del/del genotype were associated with a lower prostate cancer risk, with adjusted OR: 0.69; 95% CI: 0.44, 0.98; P=0.01 and adjusted OR: 0.60; 95% CI: 0.37, 0.91; P=0.02 respectively. For *NFKBIA* -826CT and -881AG polymorphisms, a higher prostate cancer risk association was observed. Since both polymorphisms were in LD, they had an identical risk value, with adjusted OR: 1.34; 95% CI: 1.09, 1.62; P=0.02 for heterozygotes and adjusted OR: 2.83; 95% CI: 1.79, 4.50; P=0.01 for mutants.

Combined effect of *NFKB1* and *NFKBIA* polymorphisms
-----------------------------------------------------

Significant polymorphisms were evaluated for their combined effect on prostate cancer risk. The results are shown in [Table 3](#t3-medscimonit-21-1707){ref-type="table"}. With the exceptions of NFKB19--4 ATTG ins/ins + NFKBIA mutant and NFKB19-4 ATTG ins/del + NFKBIA mutant combinative genotypes, all other genotypes were significantly associated with a lower prostate cancer risk (OR\<1.00) ([Table 3](#t3-medscimonit-21-1707){ref-type="table"}).

Association of the SNPs and prostate cancer risk in people with different smoking status
----------------------------------------------------------------------------------------

The association above was analyzed separately for smokers and nonsmokers. The result is shown in [Table 4](#t4-medscimonit-21-1707){ref-type="table"}. For smokers, similar to the overall findings described above, significant association with prostate cancer risk was observed for *NFKB1*9-4 ATTG, *NFKBIA* -826CT, and -881AG polymorphisms. However, for nonsmokers, the association of *NFKB1* polymorphism was absent, and only *NFKBIA* -826CT and -881AG polymorphisms showed risk association.

For smokers, the del/del genotype of *NFKB1*9-4 ATTG polymorphism was associated with a lower prostate cancer risk, with OR: 0.42; 95% CI: 0.22, 0.80; P\<0.01, while the mutant genotypes of the *NFKBIA* -826CT and -881AG polymorphisms were associated with a higher prostate cancer risk, with OR: 2.78; 95% CI: 1.46, 5.31; P\<0.01. For nonsmokers, *NFKBIA* -826CT and -881AG polymorphisms showed a higher risk association for prostate cancer in heterozygotes and mutants, with OR: 1.38; 95% CI: 1.07, 1.78; P=0.01 for heterozygotes and OR: 3.24; 95% CI: 1.75, 6.02; P\<0.01 for mutants.

Association of the SNPs and prostate cancer risk in older and younger subjects
------------------------------------------------------------------------------

We also analyzed the association based on the age of the subjects (old *vs.* young). [Table 5](#t5-medscimonit-21-1707){ref-type="table"} shows the association of the SNPs and prostate cancer risk in older and younger subjects. The finding based on age was similar to the finding based on the smoking status above, such that for older subjects, an association was observed for *NFKB1*9-4 ATTG, *NFKBIA* -826CT, and -881AG polymorphisms, but for younger subjects the *NFKB1*9-4 ATTG association was lost.

For older subjects, the del/del genotype of *NFKB1*9-4 ATTG polymorphism was associated with a lower prostate cancer risk, with OR: 0.57; 95% CI: 0.32, 0.99; P=0.05. In contrast, *NFKBIA* -826CT and -881AG polymorphisms showed a higher risk association for prostate cancer in heterozygotes and mutants, with OR: 1.33; 95% CI: 1.02, 1.72; P=0.03 for heterozygotes and OR: 2.98; 95% CI: 1.67, 5.33; P\<0.01 for mutants. However, in younger subjects, only the mutant genotypes of *NFKBIA* -826CT and -881AG polymorphisms were associated with prostate cancer risk, with OR: 2.69; 95% CI: 1.34, 5.42; P=0.01.

Discussion
==========

NF-κB pathway proteins play an important role in modulating inflammation and other related cellular processes. Among the many NF-κB pathway proteins, the most abundant p50 (NF-κB1) has been thought to have the most important function in these cellular processes \[[@b24-medscimonit-21-1707]--[@b26-medscimonit-21-1707]\]. Regulation of p50 (NF-κB1) by its natural inhibitor, IκBα, is necessary for the former to carry out its cellular functions. The p50 (NF-κB1) and IκBα proteins were encoded by *NFKB1* and *NFKBIA* genes, respectively. Polymorphisms within these genes may alter their protein products in several ways, which in turn lead to differential cancer risk. Many studies have been performed to investigate the association of *NFKB1*9-4 ATTG ins→del, *NFKBIA* 3′ UTR A→G, -826CT and -881AG polymorphisms and risk of various cancers \[[@b15-medscimonit-21-1707]--[@b21-medscimonit-21-1707]\]. However, surprisingly little research was performed on prostate cancers. Only 2 previous studies reported on the association of *NFKB1*9-4 ATTG ins→del polymorphism and prostate cancer risk \[[@b22-medscimonit-21-1707],[@b23-medscimonit-21-1707]\], and no study has focused on *NFKBIA* polymorphisms. Moreover, the results from the 2 *NFKB1* reports contradicted one another. It is generally accepted that polymorphisms present different risk in people with different ethnic background, and that small sample sizes may cause misleading interpretation of results. These factors motivated us to perform the present study in a large sample size among Han Chinese. In this study, we excluded patients who had family history of prostate cancer because familial cancers are usually (but not always) caused by mutations in high-penetrance genes, which are rare in the general population. The present study aimed to identify low-penetrance susceptibility alleles, which, despite having modest risk modification effect, are very common in the general population. Patients who had malignancies other than prostate cancer were also excluded to prevent misidentification of susceptibility alleles associated with other cancers.

It has been well-established that many inflammatory-related cytokines, such as TGF-β, TNF-α, IL-6, and IL-8, mediate inflammation in the prostate through the NF-κB pathway \[[@b22-medscimonit-21-1707],[@b27-medscimonit-21-1707]--[@b30-medscimonit-21-1707]\]. Therefore, genes in the NF-κB pathway, notably *NFKB1* and *NFKBIA*, potentially play a role in prostate carcinogenesis. We showed that *NFKB1*9-4 ATTG ins→del, and *NFKBIA* -826CT and -881AG polymorphisms were associated with prostate cancer risk. We postulate that the polymorphisms modulate prostate cancer risk in our subjects by altering the transcription of the genes, since the polymorphisms were all located in the promoter region. For *NFKB1*9-4 ATTG polymorphism, the del allele was associated with a reduced prostate cancer risk. *In vitro* functional assay has shown that the del allele could decrease the level of transcription by approximately 2-fold \[[@b31-medscimonit-21-1707]\]. This in turn reduces the protein translation, resulting in a lower production of p50 (NF-κB1) ([Figure 1](#f1-medscimonit-21-1707){ref-type="fig"}). Since p50 (NF-κB1) plays a role in inflammation, subjects who had less of the protein (i.e., those who carried the del allele) had a reduced level of inflammation. Considering that inflammation is positively linked to prostate carcinogenesis \[[@b9-medscimonit-21-1707]--[@b12-medscimonit-21-1707]\], subjects having the del allele were associated with a decreased prostate cancer risk, which explains our observation in this study. On the other hand, for the *NFKBIA* polymorphisms, we showed that the mutant allele was associated with an increased prostate cancer risk. It has been shown previously that the mutant allele can retard the transcription of the gene \[[@b32-medscimonit-21-1707]\]. This retardation could lead to aberrant *NFKB1* expression, which results in an increased prostate cancer risk, as observed in our study ([Figure 1](#f1-medscimonit-21-1707){ref-type="fig"}).

We also found that all combinative genotypes of *NFKB1*9-4 ATTG ins→del and NFKBIA -881/-826 polymorphisms were significantly associated with prostate cancer risk, except the *NFKB1*9-4 ATTG ins/ins + *NFKBIA* mutant and *NFKB1*9-4 ATTG ins/del + NFKBIA mutant genotypes. The lack of significance of these 2 combinative genotypes could be caused by the small sample size included. It is interesting to note that all other combinative genotypes led to a reduced prostate cancer risk, which is in accordance to the effect of *NFKB1*9-4 ATTG polymorphism but not the *NFKBIA* polymorphisms. This suggests that the effect of *NFKB1*9-4 ATTG polymorphism was stronger than that of the *NFKBIA* polymorphisms. This observation was not unexpected, since the product of *NFKB1* plays a direct role in mediating inflammation, whereas that of *NFKBIA* plays an indirect role by regulating *NFKB1* expression.

There were several strengths and limitations in this study. The greatest strength was the large sample size. The combined sample size of the only 2 available studies on NF-κB pathway gene polymorphism was 487 prostate cancer patients and 513 controls \[[@b22-medscimonit-21-1707],[@b23-medscimonit-21-1707]\]. The present study alone involved 936 prostate cancer patients and 936 controls, which had a much higher statistical power than the other 2 studies combined. Another strength of this study was that we analyzed not only the overall effect of the polymorphism on prostate cancer risk, but also the effect in smokers *vs.* nonsmokers and older *vs.* younger subjects. Both smoking habits and age have been established as strong risk factors for prostate cancer \[[@b4-medscimonit-21-1707],[@b5-medscimonit-21-1707]\]. Therefore, separate analysis of the effect of the polymorphisms on subjects with different smoking habits and age was important to control the potential confounding factors. However, our study also had a limitation. We analyzed only a few polymorphisms in the NF-κB pathway. There are several other polymorphisms that could potentially modulate prostate cancer risk. However, only 4 were included in our study because we anticipated the significance of these 4 polymorphisms based on our literature review.

Conclusions
===========

The del allele of the *NFKB1*9-4 ATTG polymorphism was associated with a decreased prostate cancer risk, while the mutant allele of *NFKBIA* -826CT and -881AG polymorphisms was associated with an increased prostate cancer risk. There have been very few studies investigating the association of NF-κB pathway gene polymorphism and prostate cancer risk. Therefore, this study adds valuable information to the currently available literature on the role of these polymorphisms on prostate cancer risk.
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![Potential mechanism by which *NFKB1* and *NFKBIA* polymorphisms mediate risk of prostate cancer.](medscimonit-21-1707-g001){#f1-medscimonit-21-1707}

###### 

Frequency of *NFKB1* and *NFKBIA* genotypes.

  SNP/genotype      Patient   Control   *P* value                                                      HWE *P* value (case + control)[\*](#tfn1-medscimonit-21-1707){ref-type="table-fn"}
  ----------------- --------- --------- -------------------------------------------------------------- ------------------------------------------------------------------------------------
  *NFKB1*                               0.03[\*\*](#tfn2-medscimonit-21-1707){ref-type="table-fn"}     0.94
   Ins/ins          63        38                                                                       
   Ins/Del          339       331                                                                      
   Del/del          534       567                                                                      
  *NFKBIA* 3′ UTR                       0.58                                                           0.55
   AA               173       165                                                                      
   AG               442       458                                                                      
   GG               321       313                                                                      
  *NFKBIA* -826CT                       \<0.01[\*\*](#tfn2-medscimonit-21-1707){ref-type="table-fn"}   0.78
   CC               508       586                                                                      
   CT               356       321                                                                      
   TT               72        29                                                                       
  *NFKBIA* -881AG                       \<0.01[\*\*](#tfn2-medscimonit-21-1707){ref-type="table-fn"}   0.78
   AA               508       586                                                                      
   AG               356       321                                                                      
   GG               72        29                                                                       

HWE -- Hardy-Weinberg Equilibrium;

significant at P\<0.05.

###### 

Association of the SNPs and prostate cancer risk.

  SNP/Genotype      Patient   Control   Odds ratio (95% CI)[\*](#tfn3-medscimonit-21-1707){ref-type="table-fn"}   *P* value
  ----------------- --------- --------- ------------------------------------------------------------------------- ------------------------------------------------------------
  *NFKB1*                                                                                                         
   Ins/ins          63        38        --                                                                        --
   Ins/Del          339       331       0.69 (0.44--0.98)                                                         0.01[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}
   Del/del          534       567       0.60 (0.37--0.91)                                                         0.02[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}
  *NFKBIA* 3′ UTR                                                                                                 
   AA               173       165       --                                                                        --
   AG               442       458       0.90 (0.69--1.22)                                                         0.61
   GG               321       313       0.94 (0.68--1.32)                                                         0.84
  *NFKBIA* -826CT                                                                                                 
   CC               508       586       --                                                                        --
   CT               356       321       1.34 (1.09--1.62)                                                         0.02[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}
   TT               72        29        2.83 (1.79--4.50)                                                         0.01[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}
  *NFKBIA* -881AG                                                                                                 
   AA               508       586       --                                                                        --
   AG               356       321       1.34 (1.09--1.62)                                                         0.02[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}
   GG               72        29        2.83 (1.79--4.50)                                                         0.01[\*\*](#tfn4-medscimonit-21-1707){ref-type="table-fn"}

Adjusted to age and smoking status;

significant at P\<0.05.

###### 

Combined effect of the SNPs and prostate cancer risk.

  SNP/genotype[\*](#tfn5-medscimonit-21-1707){ref-type="table-fn"}   Patient   Control   Odds ratio (95% CI)   *P* value
  ------------------------------------------------------------------ --------- --------- --------------------- ------------------------------------------------------------
  *NFKB1* + *NFKBIA*                                                                                           
   Ins/ins + WT                                                      35        16        --                    --
   Ins/Del + WT                                                      186       186       0.46 (0.24--0.85)     0.01[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}
   Del/del + WT                                                      285       306       0.42 (0.23--0.79)     0.01[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}
   Ins/ins + Het                                                     22        28        0.36 (0.16--0.81)     0.01[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}
   Ins/Del + Het                                                     127       119       0.49 (0.26--0.93)     0.03[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}
   Del/del + Het                                                     207       219       0.43 (0.23--0.80)     0.01[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}
   Ins/ins + Mut                                                     6         4         0.69 (0.17--2.77)     0.60
   Ins/Del + Mut                                                     26        26        0.46 (0.20--1.02)     0.06
   Del/del + Mut                                                     40        42        0.44 (0.21--0.91)     0.03[\*\*](#tfn6-medscimonit-21-1707){ref-type="table-fn"}

WT -- CC for -826 polymorphism, AA for -881 polymorphism; Het -- CT for -826 polymorphism, AG for -881 polymorphism; Mut -- TT for -826 polymorphism, GG for -881 polymorphism;

significant at P\<0.05.

###### 

Association of the SNPs and prostate cancer risk in people with different smoking status.

  Smoking status   SNP/genotype      Patient   Control   Odds ratio (95% CI)   *P* value
  ---------------- ----------------- --------- --------- --------------------- ------------------------------------------------------------
  Smokers          *NFKB1*                                                     
                    Ins/ins          **31**    **14**    --                    --
                    Ins/Del          155       130       0.54 (0.27--1.06)     0.07
                    Del/del          226       245       0.42 (0.22--0.80)     \<0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* 3′ UTR                                             
                    AA               68        77        --                    --
                    AG               207       184       1.27 (0.89--1.87)     0.21
                    GG               137       128       1.21 (0.81--1.82)     0.35
                   *NFKBIA* -826CT                                             
                    CC               213       237       --                    --
                    CT               164       138       1.32 (0.99--1.77)     0.06
                    TT               35        14        2.78 (1.46--5.31)     \<0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* -881AG                                             
                    AA               213       237       --                    --
                    AG               164       138       1.32 (0.99--1.77)     0.06
                    GG               35        14        2.78 (1.46--5.31)     \<0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
  Nonsmokers       *NFKB1*                                                     
                    Ins/ins          32        24        --                    --
                    Ins/Del          184       201       0.69 (0.40--1.21)     0.19
                    Del/del          308       322       0.72 (0.41--1.25)     0.24
                   *NFKBIA* 3′ UTR                                             
                    AA               105       88        --                    --
                    AG               235       274       0.72 (0.52--1.01)     0.05
                    GG               184       185       0.83 (0.59--1.18)     0.31
                   *NFKBIA* -826CT                                             
                    CC               295       388       --                    --
                    CT               192       183       1.38 (1.07--1.78)     0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
                    TT               37        15        3.24 (1.75--6.02)     \<0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* -881AG                                             
                    AA               295       388       --                    --
                    AG               192       183       1.38 (1.07--1.78)     0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}
                    GG               37        15        3.24 (1.75--6.02)     \<0.01[\*](#tfn7-medscimonit-21-1707){ref-type="table-fn"}

Significant at P\<0.05.

###### 

Association of the SNPs and prostate cancer risk in older and younger subjects.

  Smoking status   SNP/genotype      Patient   Control   Odds ratio (95% CI)   P value
  ---------------- ----------------- --------- --------- --------------------- ------------------------------------------------------------
  Old              *NFKB1*                                                     
                    Ins/ins          36        21        --                    --
                    Ins/Del          186       184       0.59 (0.33--1.05)     0.07
                    Del/del          302       311       0.57 (0.32--0.99)     0.05[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* 3′ UTR                                             
                    AA               100       88        --                    --
                    AG               224       256       0.77 (0.55--1.08)     0.13
                    GG               180       172       0.92 (0.65--1.31)     0.65
                   *NFKBIA* -826CT                                             
                    CC               288       332       --                    --
                    CT               192       167       1.33 (1.02--1.72)     0.03[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
                    TT               44        17        2.98 (1.67--5.33)     \<0.01[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* -881AG                                             
                    AA               288       332       --                    --
                    AG               192       167       1.33 (1.02--1.72)     0.03[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
                    GG               44        17        2.98 (1.67--5.33)     \<0.01[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
  Young            *NFKB1*                                                     
                    Ins/ins          25        17        --                    --
                    Ins/Del6         155       147       0.72 (0.37--1.38)     0.32
                    Del/del          232       256       0.62 (0.32--1.17)     0.14
                   *NFKBIA* 3′ UTR                                             
                    AA               73        77        --                    --
                    AG               198       202       1.03 (0.71--1.50)     0.86
                    GG               141       141       1.05 (0.71--1.57)     0.79
                   *NFKBIA* -826CT                                             
                    CC               220       254       --                    --
                    CT               164       154       1.23 (0.93--1.63)     0.15
                    TT               28        12        2.69 (1.34--5.42)     0.01[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}
                   *NFKBIA* -881AG                                             
                    AA               220       254       --                    --
                    AG               164       154       1.23 (0.93--1.63)     0.15
                    GG               28        12        2.69 (1.34--5.42)     0.01[\*](#tfn8-medscimonit-21-1707){ref-type="table-fn"}

Significant at P\<0.05.
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